Evaxion Biotech A/S ADR (EVAX)

$1.66 +0.02 (1.22%)
Market Cap 2.30M
Revenue (ttm) 3.34M
Net Income (ttm) -10.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -316.47%
Debt to Equity Ratio -4.95
Volume 57,600
Avg Vol 68,002
Day's Range N/A - N/A
Shares Out 1.40M
Stochastic %K 76%
Beta -0.24
Analysts Strong Sell
Price Target $13.25

Company Profile

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small...

Industry: Biotechnology
Sector: Healthcare
Phone: 45 31 31 97 53
Website: evaxion.ai
Address:
Dr. Neergaards Vej, 5th Floor, Horsholm, Denmark
Manwiththeplan
Manwiththeplan Nov. 12 at 12:56 PM
$EVAX waiting patiently on a buy out bid of 1 billion.
2 · Reply
Manwiththeplan
Manwiththeplan Nov. 10 at 8:55 PM
$EVAX new CEO will start 24th of november. I dont expect any deals till thenor soon after. I hope first months of 26
0 · Reply
Bullish_Trader555
Bullish_Trader555 Nov. 10 at 12:23 PM
$EVAX Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 $SPY $LLY
0 · Reply
Iiii1ii
Iiii1ii Nov. 10 at 8:31 AM
$EVAX Delisting?
3 · Reply
BearTamerTrading
BearTamerTrading Nov. 9 at 11:28 PM
🚨 Free Trade Monday — November 10th! 🚨 Your favorite weekly event returns — 3 live sessions packed with momentum plays, real-time alerts, and full transparency 💪. Premarket Live Trading (6 AM – 9 AM) 👉 https://www.youtube.com/live/vlYDstPoN2w?si=8hh8Zzy8UCCXilYQ Market Hours (Squawk Alerts 9:30 AM – 3:55PM) 👉 https://www.youtube.com/live/Bw-au0_c-Uk?si=NqK0n4CgQhLJM6lx After Hours Live Trading (4 PM – 6 PM) 👉 https://www.youtube.com/live/Vkmzy8QOHaQ?si=PJmwfvCCAWO9oVWN No membership required — just show up and trade with the Bear Tamer Trading community 🔥 Congratulations on all the wins today team, let’s do it again next week. Enjoy your weekend. $IFRX $FTEL $CMBM $VSEE $EVAX
1 · Reply
BearTamerTrading
BearTamerTrading Nov. 9 at 1:43 PM
Watching the tickers below for continuation on Monday, good luck to my retail traders. 🔥 $IFRX — InflaRx N.V. announced successful toxicology studies for its oral C5aR inhibitor INF904 and is tracking toward topline Phase 2a data this summer, fueling speculation while attention is high.  🔥 $EVAX — Evaxion A/S is set for a major data reveal at European Society for Medical Oncology (ESMO) Oct 17 after naming its out-licensing deal with Merck & Co. and extending cash runway into 2027.  🔥 $GREE — Greenidge Generation Holdings Inc. completed a tender/exchange offer for senior notes due 2026, reducing near-term debt burden and improving optionality.  🔥 $CTNT — Cheetah Net Supply Chain Service Inc. jumped ~12.41% after improving post-earnings sentiment and increased trading volume showing renewed short-term interest. Catch you guys on the free live trading session tomorrow November 10th, starting at 6am.
0 · Reply
CrassVee
CrassVee Nov. 9 at 12:49 PM
*weekly watchlist for plays* no set-up's/entry. There are obviously more to watch Friends, but I aim to diversify the list some with new-ish or Fresh Plays while the keeping list small. @BearTamerTrading & I are doing live PM & AH callouts aiming to help retail traders from 6am-6pm. come check us out on YT for more to watch. Free Mondays & Saturday Recaps. **Always do Your DD Friends & GL to ALL** $CMBM $EVAX $VSEE $NTLA $ACHR
1 · Reply
crystalfang
crystalfang Nov. 8 at 6:05 AM
$EVAX
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Nov. 8 at 5:43 AM
$EVAX Massive increase in volume compared to the average with over 290,000 shares traded. Price has been relatively stable around $6. Smart move might be waiting for a lower H% before considering entry.
0 · Reply
BreakoutBullz
BreakoutBullz Nov. 7 at 11:14 PM
$EVAX Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01
0 · Reply
Latest News on EVAX
Evaxion announce 2026 financial calendar

Nov 12, 2025, 8:00 AM EST - 2 days ago

Evaxion announce 2026 financial calendar

Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Nov 7, 2025, 5:10 PM EST - 7 days ago

Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Evaxion A/S (EVAX) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 7:56 PM EST - 8 days ago

Evaxion A/S (EVAX) Q3 2025 Earnings Call Transcript

Evaxion announces business update and third quarter 2025 financial results

Nov 6, 2025, 7:30 AM EST - 8 days ago

Evaxion announces business update and third quarter 2025 financial results

Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate

Nov 3, 2025, 9:00 AM EST - 11 days ago

Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate

Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

Oct 31, 2025, 9:05 AM EDT - 14 days ago

Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

Oct 31, 2025, 8:00 AM EDT - 14 days ago

Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

Evaxion raises $7.2 million, extending cash runway to second half of 2027

Oct 30, 2025, 8:00 AM EDT - 15 days ago

Evaxion raises $7.2 million, extending cash runway to second half of 2027

Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer

Oct 27, 2025, 8:00 AM EDT - 18 days ago

Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer

Evaxion A/S (EVAX) Discusses 2-Year Phase II Data and AI Immunology Platform in High-Risk Melanoma Transcript

Oct 22, 2025, 5:13 PM EDT - 23 days ago

Evaxion A/S (EVAX) Discusses 2-Year Phase II Data and AI Immunology Platform in High-Risk Melanoma Transcript

Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Oct 17, 2025, 8:15 AM EDT - 4 weeks ago

Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Oct 13, 2025, 8:00 AM EDT - 4 weeks ago

Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Evaxion expands AI-Immunology™ platform with automated vaccine design module

Oct 8, 2025, 8:12 AM EDT - 5 weeks ago

Evaxion expands AI-Immunology™ platform with automated vaccine design module

Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting

Oct 3, 2025, 9:00 AM EDT - 6 weeks ago

Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting

Evaxion A/S - Special Call

Sep 25, 2025, 11:07 AM EDT - 7 weeks ago

Evaxion A/S - Special Call

Evaxion out-licenses vaccine candidate EVX-B3 to MSD

Sep 25, 2025, 7:00 AM EDT - 7 weeks ago

Evaxion out-licenses vaccine candidate EVX-B3 to MSD

Evaxion A/S (EVAX) Q2 2025 Earnings Call Transcript

Aug 19, 2025, 3:29 PM EDT - 3 months ago

Evaxion A/S (EVAX) Q2 2025 Earnings Call Transcript

Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

Aug 11, 2025, 8:00 AM EDT - 3 months ago

Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Jul 25, 2025, 9:00 AM EDT - 4 months ago

Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Evaxion finalizes agreement with EIB to convert debt into equity

Jul 11, 2025, 8:00 AM EDT - 4 months ago

Evaxion finalizes agreement with EIB to convert debt into equity

Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio

Jul 1, 2025, 8:30 AM EDT - 4 months ago

Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio

Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus

Jun 25, 2025, 8:00 AM EDT - 5 months ago

Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus

Evaxion receives grant funding to design new polio vaccine

Jun 3, 2025, 9:15 AM EDT - 5 months ago

Evaxion receives grant funding to design new polio vaccine

Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call Transcript

May 27, 2025, 10:43 AM EDT - 6 months ago

Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call Transcript

Evaxion announces business update and first quarter 2025 financial results

May 27, 2025, 7:30 AM EDT - 6 months ago

Evaxion announces business update and first quarter 2025 financial results

Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025

May 26, 2025, 8:47 AM EDT - 6 months ago

Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025

Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025

May 23, 2025, 8:00 AM EDT - 6 months ago

Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

May 22, 2025, 8:00 AM EDT - 6 months ago

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

Apr 28, 2025, 8:00 AM EDT - 7 months ago

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

Evaxion to present at World Vaccine Congress

Apr 10, 2025, 8:00 AM EDT - 7 months ago

Evaxion to present at World Vaccine Congress

Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Call Transcript

Apr 1, 2025, 11:21 AM EDT - 8 months ago

Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Call Transcript

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

Mar 27, 2025, 8:00 AM EDT - 8 months ago

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

Mar 25, 2025, 4:30 PM EDT - 8 months ago

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

Feb 25, 2025, 8:00 AM EST - 9 months ago

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

Evaxion announces closing of $10.8 million public offering

Jan 31, 2025, 4:05 PM EST - 10 months ago

Evaxion announces closing of $10.8 million public offering

Evaxion announces pricing of $10.8 million public offering

Jan 30, 2025, 8:00 AM EST - 10 months ago

Evaxion announces pricing of $10.8 million public offering

Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement

Jan 28, 2025, 8:15 AM EST - 10 months ago

Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement

Evaxion announces completion of ADS ratio change

Jan 14, 2025, 4:05 PM EST - 10 months ago

Evaxion announces completion of ADS ratio change

Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change

Jan 10, 2025, 8:00 AM EST - 11 months ago

Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change

Evaxion announces plan to implement ADS ratio change

Dec 30, 2024, 8:00 AM EST - 11 months ago

Evaxion announces plan to implement ADS ratio change

Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1

Nov 12, 2024, 8:00 AM EST - 1 year ago

Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1

Evaxion announces business update and third quarter 2024 financial results

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Evaxion announces business update and third quarter 2024 financial results

Evaxion to announce business update and third quarter 2024 financial results on October 31

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Evaxion to announce business update and third quarter 2024 financial results on October 31

Strong validation of Evaxion's AI-Immunology™ platform in multiple clinical trials

Oct 9, 2024, 8:00 AM EDT - 1 year ago

Strong validation of Evaxion's AI-Immunology™ platform in multiple clinical trials

Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform

Oct 3, 2024, 8:00 AM EDT - 1 year ago

Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform

Evaxion Biotech Partners With Merck To Expand Vaccine Development

Sep 26, 2024, 10:53 AM EDT - 1 year ago

Evaxion Biotech Partners With Merck To Expand Vaccine Development

MRK

Evaxion significantly expands vaccine development collaboration with MSD

Sep 26, 2024, 7:30 AM EDT - 1 year ago

Evaxion significantly expands vaccine development collaboration with MSD

Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction

Sep 19, 2024, 8:00 AM EDT - 1 year ago

Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction

Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2

Evaxion Biotech A/S (EVAX) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 11:43 AM EDT - 1 year ago

Evaxion Biotech A/S (EVAX) Q2 2024 Earnings Call Transcript

Manwiththeplan
Manwiththeplan Nov. 12 at 12:56 PM
$EVAX waiting patiently on a buy out bid of 1 billion.
2 · Reply
Manwiththeplan
Manwiththeplan Nov. 10 at 8:55 PM
$EVAX new CEO will start 24th of november. I dont expect any deals till thenor soon after. I hope first months of 26
0 · Reply
Bullish_Trader555
Bullish_Trader555 Nov. 10 at 12:23 PM
$EVAX Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 $SPY $LLY
0 · Reply
Iiii1ii
Iiii1ii Nov. 10 at 8:31 AM
$EVAX Delisting?
3 · Reply
BearTamerTrading
BearTamerTrading Nov. 9 at 11:28 PM
🚨 Free Trade Monday — November 10th! 🚨 Your favorite weekly event returns — 3 live sessions packed with momentum plays, real-time alerts, and full transparency 💪. Premarket Live Trading (6 AM – 9 AM) 👉 https://www.youtube.com/live/vlYDstPoN2w?si=8hh8Zzy8UCCXilYQ Market Hours (Squawk Alerts 9:30 AM – 3:55PM) 👉 https://www.youtube.com/live/Bw-au0_c-Uk?si=NqK0n4CgQhLJM6lx After Hours Live Trading (4 PM – 6 PM) 👉 https://www.youtube.com/live/Vkmzy8QOHaQ?si=PJmwfvCCAWO9oVWN No membership required — just show up and trade with the Bear Tamer Trading community 🔥 Congratulations on all the wins today team, let’s do it again next week. Enjoy your weekend. $IFRX $FTEL $CMBM $VSEE $EVAX
1 · Reply
BearTamerTrading
BearTamerTrading Nov. 9 at 1:43 PM
Watching the tickers below for continuation on Monday, good luck to my retail traders. 🔥 $IFRX — InflaRx N.V. announced successful toxicology studies for its oral C5aR inhibitor INF904 and is tracking toward topline Phase 2a data this summer, fueling speculation while attention is high.  🔥 $EVAX — Evaxion A/S is set for a major data reveal at European Society for Medical Oncology (ESMO) Oct 17 after naming its out-licensing deal with Merck & Co. and extending cash runway into 2027.  🔥 $GREE — Greenidge Generation Holdings Inc. completed a tender/exchange offer for senior notes due 2026, reducing near-term debt burden and improving optionality.  🔥 $CTNT — Cheetah Net Supply Chain Service Inc. jumped ~12.41% after improving post-earnings sentiment and increased trading volume showing renewed short-term interest. Catch you guys on the free live trading session tomorrow November 10th, starting at 6am.
0 · Reply
CrassVee
CrassVee Nov. 9 at 12:49 PM
*weekly watchlist for plays* no set-up's/entry. There are obviously more to watch Friends, but I aim to diversify the list some with new-ish or Fresh Plays while the keeping list small. @BearTamerTrading & I are doing live PM & AH callouts aiming to help retail traders from 6am-6pm. come check us out on YT for more to watch. Free Mondays & Saturday Recaps. **Always do Your DD Friends & GL to ALL** $CMBM $EVAX $VSEE $NTLA $ACHR
1 · Reply
crystalfang
crystalfang Nov. 8 at 6:05 AM
$EVAX
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Nov. 8 at 5:43 AM
$EVAX Massive increase in volume compared to the average with over 290,000 shares traded. Price has been relatively stable around $6. Smart move might be waiting for a lower H% before considering entry.
0 · Reply
BreakoutBullz
BreakoutBullz Nov. 7 at 11:14 PM
$EVAX Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01
0 · Reply
Bullish_Trader555
Bullish_Trader555 Nov. 7 at 10:18 PM
$EVAX Ticker: EVAX (NASDAQ) Event: SITC 2025 poster presentation – new immune-response data for EVX-01, Evaxion’s AI-designed personalized cancer vaccine. Highlights: Trial: Phase 2 study in advanced melanoma, EVX-01 + KEYTRUDA® (pembrolizumab, Merck). Findings: Rapid & sustained induction of vaccine-specific T-cells in responding patients → confirms immune activation & durability seen in prior 2-year efficacy readout (ESMO 2025). Platform impact: Validates Evaxion’s AI-Immunology™ approach to designing multi-neoantigen vaccines. Partnership link: KEYTRUDA® collaboration = external validation by Merck & Co. Why it matters: Adds biological proof that EVX-01 elicits clinically relevant T-cell immunity. Strengthens Evaxion’s pitch for a Phase 3 move or a deeper Merck partnership. Typical short-term effect: biotech-catalyst volatility / speculative volume spike. Peers / related tickers: MRNA, BNTX, IMCR, GRTS, ADAP (personalized cancer-vaccine & immunotherapy sector).
1 · Reply
saunderswe
saunderswe Nov. 7 at 10:17 PM
$EVAX https://evaxion.ai/investors/press-releases/
0 · Reply
Lenni_D
Lenni_D Nov. 7 at 10:16 PM
$EVAX https://evaxion.ai/investors/press-releases/?press_release_id=10761
0 · Reply
saunderswe
saunderswe Nov. 7 at 10:14 PM
$EVAX 😳🤪
0 · Reply
sdavey1234
sdavey1234 Nov. 7 at 10:14 PM
$EVAX there she goes
0 · Reply
lestatk
lestatk Nov. 7 at 9:25 PM
$EVAX 🚀
0 · Reply
Catracho5
Catracho5 Nov. 7 at 12:25 PM
$EVAX When $20+?
1 · Reply
Manwiththeplan
Manwiththeplan Nov. 6 at 9:43 PM
$EVAX strong day on a red day
0 · Reply
Manwiththeplan
Manwiththeplan Nov. 6 at 6:09 PM
$EVAX i will wait patiently for the deals to come.
0 · Reply
MT25
MT25 Nov. 6 at 3:36 PM
$EVAX Listen about 4.30 in the interview https://finance.yahoo.com/video/cathie-wood-makes-case-elon-141539698.html
1 · Reply
IWantMyTwoDollars_1985
IWantMyTwoDollars_1985 Nov. 6 at 2:48 PM
$EVAX a lot of potential energy stored up in this one...catalyst this morning with ER. Will it ignite? Cash runway into late 2027...
0 · Reply
MT25
MT25 Nov. 6 at 1:31 PM
$EVAX brilliant update! Just listen to Cathie Wood on Bloomberg. Will get the clip asap! She is super bullish on biotech Ai 👍💪
1 · Reply